Clinical Trial Update: MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating MIL62 plus lenalidomide for relapsed/refractory indolent non-Hodgkin's lymphoma (follicular lymphoma and marginal zone …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• MIL62

Snippet

Sponsor: Beijing Mabworks Biotech Co., Ltd. | Conditions: Follicular Lymphoma and Marginal Zone Lymphoma | Phase 1, Phase 2 | Status: RECRUITING